Chromium memorial sloan kettering malignant fibrous histiocytoma treatment cancer center

This Web site — Information About Herbs, Botanicals and Other Products — is for general health information only. This Web site is not to be used as a malignant fibrous histiocytoma treatment substitute for medical advice, diagnosis or treatment of any health condition or problem. Users of this Web site should not rely on information malignant fibrous histiocytoma treatment provided on this Web site for their own health problems. Any questions regarding your own health should be addressed to malignant fibrous histiocytoma treatment your own physician or other healthcare provider.

Memorial Sloan Kettering Cancer Center makes no warranties nor express malignant fibrous histiocytoma treatment or implied representations whatsoever regarding the accuracy, completeness, timeliness, comparative or controversial nature, or usefulness of any information contained or referenced on this malignant fibrous histiocytoma treatment Web site. Memorial Sloan Kettering does not assume any risk whatsoever for malignant fibrous histiocytoma treatment your use of this website or the information contained herein. Health-related information changes frequently and therefore information contained on this malignant fibrous histiocytoma treatment Web site may be outdated, incomplete or incorrect. Statements made about products have not been evaluated by the malignant fibrous histiocytoma treatment Food and Drug Administration. Use of this Web site does not create an expressed malignant fibrous histiocytoma treatment or implied physician-patient relationship.

Memorial Sloan Kettering does not record specific website user information malignant fibrous histiocytoma treatment and does not contact users of this website. You are hereby advised to consult with a physician or malignant fibrous histiocytoma treatment other professional health-care provider prior to making any decisions, or undertaking any actions or not undertaking any actions related malignant fibrous histiocytoma treatment to any health care problem or issue you might have malignant fibrous histiocytoma treatment at any time, now or in the future. In using this website you agree that neither Memorial Sloan malignant fibrous histiocytoma treatment Kettering nor any other party is or will be liable malignant fibrous histiocytoma treatment or otherwise responsible for any decision made or any action malignant fibrous histiocytoma treatment taken or any action not taken due to your use malignant fibrous histiocytoma treatment of any information presented at this website.

Although most people consume adequate amounts through diet, chromium deficiency has been implicated in the development of diabetes malignant fibrous histiocytoma treatment (25). In vitro studies suggest that chromium produces beneficial modulatory effects malignant fibrous histiocytoma treatment under hyperglycemic conditions (26). Animal models also suggest antidiabetic (27) (28), antidepressant (29) (30) (31), and anxiolytic (32) properties.

In human studies, chromium supplementation with biotin may help to improve glycemic control malignant fibrous histiocytoma treatment in type 2 diabetes (T2D) (4) (5) (6), but results from other studies on chromium alone are mixed malignant fibrous histiocytoma treatment (33) (44). Another study showed that chromium picolinate may increase satiety (15). However, many clinical studies failed to demonstrate improvements in glucose metabolism, weight loss, or muscle mass (3) (7) (8) (9) (10) (11) (12) (13) (14). More recently one meta-analysis suggested that overall, chromium monosupplementation improved glycemic control and lipid profiles (34), while another determined that chromium picolinate did not affect A1C malignant fibrous histiocytoma treatment or fasting plasma glucose (35). It has been posited that mixed and modest effect sizes malignant fibrous histiocytoma treatment may reflect a greater glucoregulatory effect in complex patients with malignant fibrous histiocytoma treatment comorbid diabetes, depression, and binge eating (36). A large population study suggests that those who consumed chromium-containing supplements had a reduced risk of T2D compared with malignant fibrous histiocytoma treatment those who did not, and that more study is needed (37).

In women with polycystic ovary syndrome (PCOS), chromium supplementation did not affect endocrine profiles, and nitric oxide or glutathione levels, but did reduce acne, hirsutism, C-reactive protein, total antioxidant capacity, and malondialdehyde levels (45). However, meta-analyses suggest that for PCOS patients, chromium supplementation may not have significant benefits (46) or the magnitude of effect is small, with clinical relevance uncertain (47).

Chromium is poorly absorbed following oral administration, but salt forms such as chromium picolinate, niacin-bound chromium, and chromium chloride, appear to have better bioavailability. Other novel chromium compounds also have improved bioavailability (40) (41). Adverse effects are rare but can include renal failure (18) (19), rhabdomyolysis (20), liver damage (21), and dermatitis (22).

Chromium is an essential trace element involved with glucose and malignant fibrous histiocytoma treatment lipid metabolism, circulating insulin levels, and the peripheral activity of insulin (1). In vitro and in vivo studies suggest that chromium potentiates malignant fibrous histiocytoma treatment the activity of insulin (23) (42). This is thought to occur via enhanced intracellular tyrosine kinase malignant fibrous histiocytoma treatment activity that results from an interaction between chromium, low molecular weight chromium-binding substance, and activated cell surface insulin receptors (2).

In animal models of diabetes, chromium recovered beta cell functioning and alleviated macroangiopathy (27). It also augmented the insulin signaling pathway, dulled negative-regulators of insulin signaling, enhanced adenosine monophosphate-activated protein kinase (AMPK) activity to increase cellular glucose uptake, and attenuated oxidative stress (42). Chromium may also modulate peroxisome proliferator-activated receptor-gamma (PPAR-gamma), insulin receptor substrate (IRS-1), and nuclear factor-kappaB (NF-κB) proteins (28). Antidepressant effects occur via modified brain 5-hydroxytryptamine receptor (5-HT) function and increased serotonergic and noradrenergic functioning (30) (31). Additional mechanisms for antidepressant and anxiolytic effects include the lowering malignant fibrous histiocytoma treatment of plasma corticosterone levels via reversal of hypothalamic–pituitary–adrenal axis ( HPA) axis overactivity (32). In humans, suggested antidepressant mechanisms include 5HT2A downregulation and increased insulin sensitivity malignant fibrous histiocytoma treatment (38).

RELATED POSTS